| Cycling cancer persister cells arise from lineages with distinct programs Y Oren, M Tsabar, MS Cuoco, L Amir-Zilberstein, HF Cabanos, JC Hütter, ... Nature 596 (7873), 576-582, 2021 | 261 | 2021 |
| Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer S Raoof, IJ Mulford, H Frisco-Cabanos, V Nangia, D Timonina, E Labrot, ... Oncogene 38 (37), 6399-6413, 2019 | 178 | 2019 |
| Emerging insights into targeted therapy-tolerant persister cells in cancer HF Cabanos, AN Hata Cancers 13 (11), 2666, 2021 | 94 | 2021 |
| Therapy-induced APOBEC3A drives evolution of persistent cancer cells H Isozaki, R Sakhtemani, A Abbasi, N Nikpour, M Stanzione, S Oh, ... Nature 620 (7973), 393-401, 2023 | 30 | 2023 |
| Small-molecule-induced clustering of heparan sulfate promotes cell adhesion N Takemoto, T Suehara, HL Frisco, S Sato, T Sezaki, K Kusamori, ... Journal of the American Chemical Society 135 (30), 11032-11039, 2013 | 26 | 2013 |
| Synthetic molecules that protect cells from anoikis and their use in cell transplantation HL Frisco‐Cabanos, M Watanabe, N Okumura, K Kusamori, N Takemoto, ... Angewandte Chemie 126 (42), 11390-11395, 2014 | 23 | 2014 |
| APOBEC3A drives acquired resistance to targeted therapies in non-small cell lung cancer H Isozaki, A Abbasi, N Nikpour, A Langenbucher, W Su, M Stanzione, ... BioRxiv, 2021.01. 20.426852, 2021 | 18 | 2021 |
| Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer KE Poels, AJ Schoenfeld, A Makhnin, Y Tobi, Y Wang, H Frisco-Cabanos, ... Nature communications 12 (1), 3697, 2021 | 17 | 2021 |
| Hü tter Y Oren, M Tsabar, MS Cuoco, L Amir-Zilberstein, HF Cabanos JC, Hu, B., Thakore, PI, Tabaka, M., Fulco, CP, et al, 576-582, 2021 | 8 | 2021 |
| Cycling cancer persister cells arise from lineages with distinct transcriptional and metabolic programs Y Oren, M Tsabar, HF Cabanos, MS Cuoco, E Zaganjor, PI Thakore, ... bioRxiv, 2020.06. 05.136358, 2020 | 7 | 2020 |
| Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer (vol 12, 3697, 2021) KE Poels, AJ Schoenfeld, A Makhnin, Y Tobi, Y Wang, H Frisco-Cabanos, ... NATURE COMMUNICATIONS 13 (1), 2022 | 1 | 2022 |
| Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer KE Poels, AJ Schoenfeld, A Makhnin, Y Tobi, Y Wang, H Frisco-Cabanos, ... nature communications 13, 2022 | | 2022 |
| Targeting the root of cancer persister cells using an expressed barcode library Y Oren, P Thakore, MS Cuoco, HF Cabanos, A Hata, JS Brugge, A Regev Cancer Research 79 (13_Supplement), 2101-2101, 2019 | | 2019 |
| アノイキスから細胞を守る合成分子の創製と細胞移植への利用に関する研究 小野瑞穂 | | 2016 |
| Synthetic Molecules that Protect Cells from Anoikis and Their Use in Cell Transplantation. HL FRISCO Kyoto University, 2015 | | 2015 |
